Mycophenolat Mofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolat Mofetil Accord, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. Approved in the European Union, it is employed to prevent acute rejection after kidney, heart or liver transplantation, to treat lupus nephritis, and to manage certain autoimmune diseases in adult patients.

GNH USA supplies Mycophenolat Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in immunosuppressive therapy to control immune‑mediated rejection and autoimmune activity.

- Kidney transplantation: helps prevent acute graft rejection and supports long‑term graft survival. - Heart transplantation: reduces incidence of acute rejection episodes post‑surgery. - Liver transplantation: maintains graft function by suppressing immune response. - Lupus nephritis: improves renal outcomes by decreasing disease activity. - Certain autoimmune disorders: controls disease activity in conditions such as vasculitis or dermatomyositis.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate intensity. - Elevated liver enzymes: mild transaminase elevations.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Bone marrow failure: aplastic anemia or pancytopenia. - Renal toxicity: acute kidney injury. - Malignancy: increased risk of post‑transplant lymphoproliferative disorder.

When prescribing Mycophenolate Mofetil, clinicians should observe several safety precautions to minimize risks.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Breastfeeding: not recommended; drug may be excreted in milk. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Infection risk: screen for latent infections and monitor for new infections. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours. - Azathioprine: additive bone‑marrow suppression; avoid concurrent use. - Live vaccines: increased risk of infection; avoid administration while on therapy.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate levels; monitor blood counts. - Rifampin: induces metabolism, decreasing mycophenolate exposure; adjust dose if needed. - Cholestyramine: binds drug and reduces bioavailability; separate dosing.